Here, we screened a preclinical/clinical compound library consisting of 3471 bioactive compounds and identified embelin, a potent nonpeptide cell‐permeable inhibitor of XIAP, specifically targeting SHP2, establishing a connection between these two cancer‐related proteins for the first time. Here, XIAP is linked to cancer.